Synthon Holding

Synthon Holding, established in 1991, is a biopharmaceutical company evolving into a specialty pharmaceutical entity. It focuses on developing a promising portfolio of next-generation medicines, targeting oncology and auto-immune diseases. The company initiated its biopharmaceutical franchise in 2007, demonstrating a strategic shift towards advanced therapeutic solutions. Synthon Holding operates with 1,000 to 5,000 employees across 5 locations, underscoring its significant operational footprint. Its product development encompasses high-quality generic and complex medicines, including antibody-drug conjugates (ADCs) and bioequivalent versions, aimed at improving patient access to critical treatments.

The company's commitment to innovation is evident in its development pipeline and strategic focus on complex generics and biosimilars. Synthon Holding leverages expertise in pharmaceutical development and manufacturing to commercialize products through licensing and business-to-business partnerships. For insights into the people driving this innovation, you can Meet Synthon Holding's team. The company's revenue reached $273.7M, reflecting its market presence and financial performance within the pharmaceutical sector.

Operating within the Pharmaceuticals and Healthcare industries, Synthon Holding's URL is www.synthon.com. The company's strategic direction emphasizes building a robust portfolio of advanced therapies to address unmet medical needs. Its focus on high-quality manufacturing and commercialization strategies positions it as a key player in the global pharmaceutical landscape, contributing to patient care through accessible and effective medicines.